Why the study?
Does combination therapy with temocapril and azelnidipine improve renoprotective effects compared to monotherapy in a spontaneously hypertensive rat remnant kidney model?
Does combination therapy with temocapril and azelnidipine improve renoprotective effects compared to monotherapy in a spontaneously hypertensive rat remnant kidney model?
Combination therapy with an ACE inhibitor and a calcium antagonist provides greater renoprotection than monotherapy in a hypertensive rat model of chronic renal failure.
No takes yet. Share an insight, caveat, or question.
Should not change practice; hypothesis-generating for additive renoprotection in hypertensive rat CKD models.
Kanazawa et al. (2002) studied this question.